MK-8189

MK-8189
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-Methyl-6-[[(1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine;
CAS Number	1424371-93-6;
PubChem CID	71271414;
ChemSpider	128922007;
UNII	7M430JI73B;
Chemical and physical data
Formula	C19H22N6OS
Molar mass	382.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CN=C(C=C1)[C@H]2C[C@@H]2COC3=NC(=NC(=C3)NCC4=NN=C(S4)C)C;
	InChI InChI=1S/C19H22N6OS/c1-11-4-5-16(20-8-11)15-6-14(15)10-26-18-7-17(22-12(2)23-18)21-9-19-25-24-13(3)27-19/h4-5,7-8,14-15H,6,9-10H2,1-3H3,(H,21,22,23)/t14-,15+/m1/s1; Key:WQKPZDLZRFTMTI-CABCVRRESA-N;

MK-8189 is a selective phosphodiesterase 10A inhibitor being developed for schizophrenia. It is developed by Merck in collaboration with Royalty Pharma.^[1]^[2]^[3]^[4]